PharmaCyte Biotech, Inc.
PMCB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001157075
No open-market purchases or sales by PharmaCyte Biotech, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $586.2K in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding PharmaCyte Biotech, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 30 | 28 | −2 |
| Shares | 3.47M | 3.84M | +369.4K (+10.6%) |
| Value | $8.68M | $8.83M | +$150.9K (+1.7%) |
New holders (4)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| FNY Investment Advisers, LLC | 59,066 | $135.0K | 0.13% |
| State Street Corp | 37,600 | $86.0K | 0.00% |
| Susquehanna International Group, LLP | 28,062 | $65.0K | 0.00% |
| JPMorgan Chase & Co | 2,723 | $6.00K | 0.00% |
Sold out (6)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Anson Funds Management LP | 193,400 | $484.0K |
| Marshall Wace, LLP | 13,515 | $35.0K |
| Jump Financial, LLC | 10,300 | $26.0K |
| Tower Research Capital LLC (TRC) | 650 | $2.00K |
| CWM, LLC | 1 | $0 |
| Comprehensive Financial Consultants Institutional, Inc. | 14 | $0 |